

**International Textbook of Diabetes Mellitus, 4th Ed., Chapter 10 –
Biosynthesis, secretion, and action of glucagon**

References:

1. Lefèbvre PJ: Early milestones in glucagon research. *Diabetes, Obesity and Metabolism* 2011;13(Suppl 1):1–4.
2. Unger RH, Eisentraut AM, McCall MS, et al.: Glucagon antibodies and their role for immunoassay of glucagon. *Proceedings of the Society for Experimental Biology and Medicine* 1959;102: 621 – 623.
3. Unger RH, Orci L: Paracrinology of islets and the paracrinopathy of diabetes. *PNAS* 2010;107:16009–16012.
4. Lefèbvre P: Diabetes as a paracrinopathy of the islets of Langerhans. *European Endocrinology* 2011;7:79–82.
5. Lefèbvre PJ (ed.): *Glucagon. Handbook of Experimental Pharmacology*, 66, Vols I and II. Berlin: Springer, 1983.
6. Lefèbvre PJ (ed.): *Glucagon III. Handbook of Experimental Pharmacology*, 123. Berlin: Springer, 1996.
7. Cerasi E, Accili D, Ahrén B, et al. (eds.): Pancreatic α -cells and glucagon: neglected metabolic actors. *Diabetes, Obesity and Metabolism* 2011;13(Suppl 1).
8. Sherwood NM, Krueckl SL, McRory JE: The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/ glucagon superfamily. *Endocrine Reviews* 2000;21:619–670.
9. Philippe J: Structure and pancreatic expression of the insulin and glucagon genes. *Endocrine Reviews* 1991;12:252–271.
10. Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. *Gastroenterology* 2002;122:531–544.
11. Phillips LK, Prins JB: Update on incretin hormones. *Annals of the N Y Academy of Sciences* 2011;1243:E55–74.
12. Herzlinger S, Horton ES: Extraglycemic effects of GLP-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. *Diabetes Research and Clinical Practice* 2013;100(1):1 – 10.
13. Drucker DJ: Glucagon-like peptide 2. *Journal of Clinical Endocrinology & Metabolism* 2001;86:1759–1764.
14. Dube PE, Brubaker PL: Frontiers in glucagon-like peptide 2: multiple actions, multiple mediators. *American Journal of Physiology - Endocrinology and Metabolism* 2007;293:E460 – 465.
15. Rowland KJ, Brubaker PE: The “cryptic” mechanism of action of glucagon-like peptide 2. *American Journal of Physiology - Gastrointestinal and Liver Physiology* 2011;301:G1 – G8.
16. Blache P, Kervran A, Dufour M, et al.: Glucagon-(19-29), a Ca^{2+} pump inhibitory peptide, is processed from glucagon in the rat liver plasma membrane by a thiol endopeptidase. *The Journal of Biological Chemistry* 1990;265:21514 – 21519.

17. Bataille D, Jarrousse C, Blache P, et al.: Oxyntomodulin and glucagon: are the whole molecules and their C-terminal fragments different biological entities? *Biomedical Research* 1988;9(Suppl 3): 169 – 179.
18. Dalle S, Fontés G, Lajoix AD, et al.: Mini-glucagon (glucagon 19-29). A novel regulator of the pancreatic islet physiology. *Diabetes* 2002;51:406 – 412.
19. Dalle S, Smith P, Blache P, et al.: Mini-glucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca^{2+} pathway. *The Journal of Biological Chemistry* 1999;274:10869 – 10876.
20. Furuta M, Yano H, Zhou A, et al.: Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. *PNAS* 1997;94:6646–6651.
21. Furuta M, Zhou A, Webb G, et al.: Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. *The Journal of Biological Chemistry* 2001;276:27197–27202.
22. Webb GC, Akbar MS, Zhao C, et al.: Glucagon replacement via micro-osmotic pump corrects hypoglycemia and α -cell hyperplasia in prohormone convertase 2 knockout mice. *Diabetes* 2002;51: 398 – 405.
23. Gosmain Y, Cheyssac C, Heddad Masson M, et al.: Glucagon gene expression in the endocrine pancreas: the role of the transcription factor Pax6 in α -cell differentiation, glucagon biosynthesis and secretion. *Diabetes, Obesity and Metabolism* 2011;13(Suppl 1): 31–38.
24. Courtney M, Pfeifer A, Al-Hasani K, et al.: In vivo conversion of adult α -cells into β -like cells: a new research avenue in the context of type 1 diabetes. *Diabetes, Obesity and Metabolism* 2011;13 (Suppl 1):47–52.
25. Thorel F, Népote V, Avril I, et al.: Conversion of adult pancreatic α -cells to β -cells after extreme β -cell loss. *Nature* 2010;464: 1149 – 1154.
26. Buggy JJ, Heurich RO, MacDougall M, et al.: Role of the glucagon receptor COOH-terminal domain in glucagon-mediated signaling and receptor internalization. *Diabetes* 1997;46:1400–1405.
27. Unson CG, Wu CR, Cheung CP, Merrifield RB: Positively charged residues at positions 12, 17, and 18 of glucagon ensure maximum biological potency. *The Journal of Biological Chemistry* 1998;273: 10308 – 10312.
28. Parker JC, Andrews KM, Allen MR, et al.: Glycemic control in mice with targeted disruption of the glucagon receptor gene. *Biochemical and Biophysical Research Communications* 2002;290:839–843.
29. Lee Y, Wang M-Y, Du XQ, et al.: Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. *Diabetes* 2011; 60:391 – 397.
30. Hendrick GT, Wasserman DH, Tyler Frizzel R, et al.: Importance of basal glucagon in maintaining hepatic glucose production during a prolonged fast in conscious dogs. *American Journal of Physiology - Endocrinology and Metabolism* 1992;263(26):E541 – 549.

31. Rammanan CJ, Edgerton DS, Kraft G, Cherrington AD: Physiologic action of glucagon on liver glucose metabolism. *Diabetes, Obesity and Metabolism* 2011;13(Suppl 1):118 – 125.
32. Chibber VL, Soriano C, Tayek JA: Effects of low-dose and high-dose glucagon on glucose production and gluconeogenesis in humans. *Metabolism* 2000;49:39 – 46.
33. Paquot N, Schneiter Ph, Jéquier E, et al.: Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects. *Diabetologia* 1996;39:580 – 586.
34. Surmely JF, Schneiter Ph, Henry S, et al.: Effects of glucagon in the control of endogenous glucose production in man. *Nutrition* 1999;15:267 – 273
35. Paolisso G, Scheen AJ, Albert A, Lefèbvre PJ: Effects of pulsatile delivery of insulin and glucagon in humans. *American Journal of Physiology — Endocrinology and Metabolism* 1989;257(20):E686 – 696.
36. McGarryJD, FosterDW: Glucagon and ketogenesis. In: Lefèbvre PJ (ed.) *Glucagon, Vol. I*. Berlin: Springer, 1983, pp. 383–398.
37. Paolisso G, Buonocore S, Gentile S, et al.: Pulsatile glucagon has greater hyperglycaemic, lipolytic and ketogenic effects than continuous hormone delivery in man: effect of age. *Diabetologia* 1990;33:272 – 277.
38. Carlson MG, Snead WL, Campbell PJ: Regulation of free fatty acid metabolism by glucagon. *Journal of Clinical Endocrinology & Metabolism* 1993;77:11–15.
39. Højberg Gravholt C, Møller N, Jensen MD, et al. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. *Journal of Clinical Endocrinology & Metabolism* 2001;86:2085–2089.
40. Bertin E, Arner P, Bolinder J, Hagström-Toft E: Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle *in vivo*. *Journal of Clinical Endocrinology & Metabolism* 2001;86:1229–1234.
41. Arafat AM, Kaczmarek P, Skrzypski M, et al.: Glucagon increases circulating growth factor 21 independently of endogenous insulin release: a novel mechanism of glucagon-stimulated lipolysis? *Diabetologia* 2013;56:588–597.
42. Moens K, Berger V, Ahn JM, et al.: Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic β -cells. *Diabetes* 2002;51:669–675.
43. Leffert HL, Koch KS, Lad PJ, et al.: Glucagon and liver regeneration. In: Lefèbvre PJ (ed.) *Glucagon, Vol. I*. Berlin: Springer, 1983, pp. 453–484.
44. Ahlouley M, Bouby N, Machel F, et al.: Effect of glucagon on glomerular filtration rate and urea and water excretion. *American Journal of Physiology. Renal, Fluid, and Electrolyte Physiology* 1992; 263(32):F24 – 36.

45. Grossman E, Goldstein DS, Hoffman A, et al.: Glucagon and clonidine testing in the diagnosis of pheochromocytoma. *Hypertension* 1991;17:733 – 741.
46. Farah AH: Glucagon and the heart. In: Lefèbvre PJ (ed.) *Glucagon, Vol II*. Berlin: Springer, 1983, pp. 553–609.
47. Melanson SW, Bonfante G, Heller MB: Nebulized glucagon in the treatment of bronchospasm in asthmatic patients. *American Journal of Emergency Medicine* 1998;16:272–275.
48. Gromada J, Franklin I, Wollheim CB: A-cells of the endocrine pancreas: 35 years of research but the enigma remains. *Endocrine Reviews* 2007;28:84–116.
49. Walker JN, Ramracheya, R, Zhang et al.: Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? *Diabetes, Obesity and Metabolism* 2011;13(Suppl 1):95 – 105.
50. Thorens B: Brain glucose sensing and neural regulation of insulin and glucagon secretion. *Diabetes, Obesity and Metabolism* 2011;13(Suppl 1):82 – 88.
51. Holst JJ, Christensen M, Lund A, et al.: Regulation of glucagon secretion by incretins. *Diabetes, Obesity and Metabolism* 2011;13 (Suppl 1):89 – 94.
52. Samols E, Weir GC, Bonner-Weir S: Intra-islet insulin – glucagon – somatostatin relationships. In: Lefèbvre PJ (ed.) *Glucagon, Vol. II*. Berlin: Springer, 1983, pp. 133 – 173.
53. Lefèbvre P, Paolisso G, Scheen AJ: Pulsatility of glucagon. In: Lefèbvre PJ (ed.) *Glucagon III. Handbook of Experimental Pharmacology*. Berlin: Springer, 1996, pp. 105 – 113.
54. Tian G, Sandler S, Gylfe E, et al. Glucose and hormone-induced cAMP oscillations in α - and β -cells within pancreatic islets. *Diabetes* 2011;60:1535 – 1543.
55. Hellman B, Salehi A, Gylfe E, et al.: Glucose generates coincident insulin and somatostatin pulses and anti-synchronous pulses from human pancreatic islets. *Endocrinology* 2009;150:5334–5340.
56. Rutter GA:Regulating glucagon secretion:somatostatin in the spotlight. *Diabetes* 2009;58:299–301.
57. Jacobson DA, Wicksteed BL, Philipson LH: The α -cell conundrum: ATP-sensitive K^+ channels and glucose sensing. *Diabetes* 2009;58:304 – 306.
58. Hauge-Evans AC, King AJ, Carmignac D, et al. Somatostatin secreted by islet δ -cells fulfils multiple roles as a paracrine regulator of islet function. *Diabetes* 2009;58:403–411.
59. Quoix N, Cheng-Xue R, Mattart L, et al.: Glucose and pharmacological modulators of ATP-sensitive K^+ channels control $[Ca^{++}]_c$ by different mechanisms in isolated mouse α -cells. *Diabetes* 2009;58:412 – 421.
60. Christensen M, Vedtofte L, Holst JJ, et al.: Glucose-dependent insulinotropic polypeptide. A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. *Diabetes* 2011;60:3103 – 3109.

61. Gaisano HY, MacDonald PE, Vranic M: Glucagon secretion and signalling in the development of diabetes. *Frontiers in Physiology: Systems Physiology* 2012;3:1–12.
62. Cryer PE: The barrier of hypoglycemia in diabetes. *Diabetes* 2008;57:3169 – 176.
63. Luyckx AS, Pirnay F, Lefèbvre PJ: Effect of glucose on plasma glucagon and free fatty acids during prolonged exercise. *European Journal of Applied Physiology* 1978;39:53–61.
64. Lindsey CA, Faloon GR, Unger RH: Plasma glucagon levels during rapid exsanguination with and without adrenergic blockade. *Diabetes* 1975;24:313–319.
65. Gelfand RA, Sherwin RS: Glucagon and starvation. In: Lefèbvre PJ (ed.) *Glucagon, Vol. II*. Berlin: Springer, 1983, pp. 223–237.
66. Girard J, Sperling M: Glucagon in the fetus and the newborn. In: Lefèbvre PJ (ed.) *Glucagon, Vol. II*. Berlin: Springer, 1983, pp. 251–274.
67. Dinneen S, Alzaid A, Turk D, Rizza R: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. *Diabetologia* 1995;38:337–343.
68. Shah P, Basu A, Basu R, Rizza R: Impact of lack of suppression of glucagon on glucose tolerance in humans. *American Journal of Physiology* 1999;277:E283–290.
69. Shah P, Vella A, Basu A, et al.: Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism* 2000;85:4053 – 4059.
70. Greenbaum CJ, Prigeon RL, D'Alessio DA: Impaired β -cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. *Diabetes* 2002;51:951 – 957.
71. Ipp E: Impaired glucose tolerance. The irrepressible α -cell? *Diabetes Care* 2000;23:569 – 570.
72. Larsson H, Åhrén B: Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in post-menopausal women with impaired glucose tolerance. *Diabetes Care* 2000;23:650 – 657.
73. Choukem SP, Sobngwi E, Boudou P, et al.: Beta- and alpha-cell dysfunction in Africans with ketosis-prone atypical diabetes during near-normoglycemic remissions. *Diabetes Care* 2013;36:118 – 123.
74. Lefèbvre P: Ketosis-prone atypical diabetes: glucagon there, too. *Diabetes Care* 2013;36:8 – 10.
75. Henquin JC, Rahier J: Pancreatic alpha cell mass in European subjects with type 2 diabetes. *Diabetologia* 2011;54:1720 – 1725.
76. Unger RH, Cherrington AD: Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. *Journal of Clinical Investigation* 2012;122:4 – 12.
77. Bosco D, Armanet M, Morel P, et al.: Unique arrangement of α - and β -cells in human islets of Langerhans. *Diabetes* 2010;59:1202 – 1210.

78. Meier JJ, Kjems LL, Veldhuis JD, et al.: Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the inraislelet insulin hypothesis. *Diabetes* 2006;55:1051 – 1056.
79. Menge BA, Grüber L, Jørgensen SM, et al.: Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. *Diabetes* 2011;60:2160 – 2168.
80. Yu X, Park BH, Wang MY, et al.: Making insulin-deficient type 1 diabetic rodents thrive without insulin. *PNAS* 2008;105:14070 – 14075. 81 Lee Y, Berglund ED, Wang MY, et al.: Metabolic manifestations of insulin deficiency do not occur without glucagon action. *PNAS*, 2012;109:14972 – 14976.
81. Ali S, Drucker DJ: Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. *American Journal of Physiology - Endocrinology and Metabolism* 2009;296:E415 – E421
82. Wermers RA, Fatourehchi V, Wynne AG, et al.: The Glucagonoma Syndrome. Clinical and pathologic features in 21 patients. *Medicine* 1996;75:53 – 63.